Updates in Treatment and Management of B-Cell Malignancies

Andre H. Goy, MD, and Andrew Ip, MD, discuss the ways in which treatment paradigms for mantle cell lymphoma (MCL) have recently shifted.

Expert oncologists give an overview of the BRUIN trial and discuss pirtobrutinib as a treatment for patients with mantle cell lymphoma.

A comprehensive overview of CAR T-cell therapy as a treatment modality for mantle cell lymphoma, including insights on the ZUMA-2 clinical trial.

Experts on B-cell malignancies discuss second-line therapy options for patients with relapsed/refractory mantle cell lymphoma.

Andre H. Goy, MD, and Andrew Ip, MD, offer insights on the future of mantle cell lymphoma treatment.

Expert oncologists discuss the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL).

An overview of the L-MIND trial of tafasitamab plus lenalidomide in patients with relapsed/refractory disease.

Experts overview the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory DLBCL, and discuss how tumor volume correlates with clinical outcomes.

Experts on diffuse large B-cell lymphoma discuss the factors that inform their treatment choices in the second line.

Andre H. Goy, MD, and Andrew Ip, MD, offer closing remarks on unmet needs in the treatment of diffuse large B-cell lymphoma.